UCLA Scientists Find Male Gene In Brain Area Targeted By Parkinson's
Main Category: Parkinson's DiseaseAlso Included In: Neurology / Neuroscience
Article Date: 22 Feb 2006 - 19:00 PDT
| Patient / Public: | ![]() |
4.33 (3 votes) |
| Healthcare Prof: | ![]() |
3 (2 votes) |
| Article Opinions: | 1 posts |
UCLA scientists have discovered that a sex gene responsible for making embryos male and forming the testes is also produced by the brain region targeted by Parkinson's disease. Published in the Feb. 21 edition of Current Biology, the new research may explain why more men than women develop the degenerative disorder, which afflicts roughly 1 million Americans.
"Men are 1.5 times more likely to develop Parkinson's disease than women," said Dr. Eric Vilain, associate professor of human genetics at the David Geffen School of Medicine at UCLA. "Our findings may offer new clues to how the disorder affects men and women differently, and shed light on why men are more susceptible to the disease."
In 1990, British researchers identified SRY as the gene that determines gender and makes embryos male. Located on the male sex chromosome, SRY manufactures a protein that is secreted by cells in the testes.
Now, in an unexpected discovery, Vilain's team became the first to trace the SRY protein to a region of the brain called the substantia nigra, which deteriorates in Parkinson's disease.
Parkinson's disease occurs when cells in the substantia nigra begin to malfunction and die. These brain cells produce a neurotransmitter called dopamine that communicates with the brain areas controlling movement and coordination.
As the cells die off, they produce less dopamine. This slows the delivery of messages from the brain to the rest of the body, leaving the person unable to initiate or control their physical movements. The condition eventually leads to paralysis.
"For the first time, we've discovered that the brain cells that produce dopamine depend upon a sex-specific gene to function properly," Vilain said. "We've also shown that SRY plays a central role not just in the male genitals, but also in regulating the brain."
Vilain's lab used a rat model to study the effect of SRY on the brain. When the researchers lowered the level of SRY in the substantia nigra, they saw a corresponding drop in an enzyme called tyrosine hydroxylase (TH), which plays a key role in the brain's production of dopamine.
In a surprise finding, the drop in TH occurred only in the male rats. The female rats remained unaffected.
"When we reduced SRY levels in the rats' brains, the male animals began experiencing the movement problems caused by insufficient dopamine," Vilain said. "Low levels of SRY triggered Parkinson's symptoms in the male rats, cutting their physical agility by half in a week.
"Initially, the rat could walk 14 steps in 10 seconds," he noted. "After we lowered the SRY levels in its brain, the rat could only manage seven steps in the same amount of time."
Vilain believes that variations in SRY levels may be linked to the onset of Parkinson's and could offer insights into who is at risk for the disease.
"SRY may serve as a protective agent against Parkinson's," he said. "Men who contract the disease may have lower levels of the gene in the brain."
Because SRY is found only in males, Vilain thinks women must possess another physiological mechanism that protects dopamine-producing cells in the substantia nigra.
"We suspect that estrogens in women could play the same role as SRY in protecting the female brain from Parkinson's disease," he said. "Our lab is currently studying this hypothesis in an animal model."
Sex differences in other dopamine-linked disorders, such as schizophrenia or addiction, may also be explained by the SRY gene, Vilain said.
"It's possible that dopamine-related disorders that reveal dramatic differences in severity and rates in the genders could depend on the SRY levels in the brain," he said.
###
The study was co-authored by Marie-Francoise Chesselet, UCLA chair of neurobiology; and Paul Micevych, UCLA professor of neurobiology; and Vincent Harley, associate professor of human molecular genetics at Prince Henry's Institute of Medical Research, Australia.
The National Institute of Child Health and Human Development and the American Parkinson's Disease Association supported the research.
Parkinson's disease is a chronic movement disorder that worsens over time. While 15 percent of people with Parkinson's are diagnosed before age 40, prevalence increases with age. The cause of Parkinson's is unknown, and there is no cure. However, medication and surgery can help manage the symptoms.
Contact: Elaine Schmidt
eschmidt@mednet.ucla.edu
University of California - Los Angeles
Visit our parkinson's disease section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/38119.php>
APA
http://www.medicalnewstoday.com/releases/38119.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Parkinson's and Reduced SRY may be due to low Testosterone and low DHEA
posted by James Michael Howard on 22 Feb 2006 at 8:24 pmIt is my hypothesis that DHEA optimizes replication and transcription of DNA. I think DHEA was selected by evolution in the formation of mammals (Hormones in Mammalian Evolution, Rivista di Biologia / Biology Forum 94: 177-184). Also, I have suggested that selection for testosterone within mammals resulted in primates (ibid 95: 319-326) with further selection for testosterone resulting in humans (ibid 94: 345-362). I think testosterone redirects DHEA use for “testosterone target tissues.” Hence, the rise in testosterone changed the physical form of mammals. This may be seen in higher DHEA in chimpanzee males and females and lower testosterone compared to human males and females. For example, the human brain is a “testosterone target tissue” and its use of extra DHEA reduces the size of faces and teeth during hominid evolution.
Dewing, et al., (Current Biology 2006; 16: 415-420) suggest that down regulation of SRY reduces tyrosine hydroxylase. Testosterone replacement has been found to significantly improve motor function in a patient with Parkinson’s (J Clin Neurosci 2006; 13: 133-6). Some of the symptoms of Parkinson’s may be produced by low testosterone. Tyrosine hydroxylase may be regulated by “androgen receptors” (Neurosci Lett 2006; 396: 57-61). DHEA acts via androgen receptors and exerts “intrinsic androgenic activity that is potentially independent of metabolic conversion to other androgens” (J Neurobiol 2003; 57: 163-71). Additionally, DHEA directly stimulates tyrosine hydroxylase (Endocrinology 2005; 146: 3309-18). I suggest testosterone is involved in directing DHEA use towards SRY activation. This could increase dopamine production as well as primate and male development.
It may be that Parkinson’s results from a combination of low testosterone and low DHEA. That is, low testosterone may exacerbate the effects of low DHEA; low testosterone is not directing DHEA sufficiently to SRY activation and low DHEA worsens this condition. Treatment with testosterone only positively affects some Parkinson’s symptoms. Adrenal medullary transplantation for Parkinson’s produces a “long-term reduction of dehydroepiandrosterone sulfate” (J Clin Endocrinol Metab 1990; 71: 773-6). DHEA sulfate is the precursor of DHEA, the active molecule. In this case, a reduction in DHEAS may indicate that DHEA is being converted from DHEAS, thus reducing DHEAS. This may be why this procedure may produce positive effects for Parkinson’s victims. That is, available DHEA is increased.
The findings of Dewing, et al., may represent findings that support treatment of Parkinson’s with testosterone and dehydroepiandrosterone.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





